Michael J. Mauro, MD, discusses the risks of disease progression in myelofibrosis.
Michael Mauro, MD
Advertisement
Articles by Michael Mauro, MD
Michael J. Mauro, MD, discusses considerations for early treatment initiation in myelofibrosis.
Michael J. Mauro, MD, discusses managing symptom burden in patients with myelofibrosis.
Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses treatment discontinuation for patients with chronic myeloid leukemia.
Advertisement
Latest Updated Articles
Dr. Mauro on Managing Symptom Burden in MyelofibrosisPublished: July 6th 2021 | Updated:
Dr. Michael Mauro on Treatment Discontinuation for CMLPublished: February 20th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5